300253 卫宁健康
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,223,7432.68%3,163,4253,092,8652,750,2022,266,580
减:营业总成本1,158,172-8.37%2,808,7462,828,5212,378,8931,766,674
    其中:营业成本717,7271.51%1,739,8181,741,6131,475,5291,040,905
               财务费用28,26712.40%51,08039,66535,5265,735
               资产减值损失(77,389)-5.47%(136,735)(129,003)(83,931)(81,937)
公允价值变动收益6,961-625.94%(50,464)(24,888)155,547(34,692)
投资收益(20,894)-163.73%29,498(65,676)(39,040)101,228
    其中:对联营企业和合营企业的投资收益(20,894)-25.24%(31,011)(46,935)(45,084)(54,815)
营业利润17,333-132.45%341,43139,502374,662551,672
利润总额17,115-131.80%340,74738,541373,168546,158
减:所得税费用(5,099)-86.30%23,13223,78319,43440,632
净利润22,214-233.79%317,61514,758353,734505,525
减:非控股权益(7,954)-76.04%(40,344)(93,882)(24,440)14,427
股东净利润30,16881.83%357,959108,640378,174491,098

市场价值指针
每股收益 (元) *0.01481.82%0.1670.0510.1770.231
每股派息 (元) *----0.0200.0100.0200.025
每股净资产 (元) *2.6239.57%2.5952.3312.3282.119
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容